AgingResearch.NewsJoin free

Corbus Pharmaceuticals

CompanyUnited States

Corbus Pharmaceuticals develops one asset, in phase 1 (CRB-913 in obese but otherwise healthy participants). Mostly small molecule acting on CNR1; based in the United States.

1
Asset
Furthest stage
Phase 1
2
Trials
1
Signal

Pipeline

1

  • CRB-913

    Peripherally restricted cannabinoid CB1 receptor inverse agonist intended to reduce body weight.

    Phase 1, Small molecule, CNR1, obese but otherwise healthy participants

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Signals2
  • Similar companies4

Intelligence